Drug Profile
Research programme: monoclonal microbials - Evelo Biosciences
Alternative Names: Monoclonal microbial therapeutics - Evelo BiosciencesLatest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator Evelo Biosciences
- Class Bacteria
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 26 Jan 2024 Discontinued - Preclinical for Metabolic disorders in USA (PO)
- 13 Dec 2019 Early research in Metabolic disorders in USA (PO) (Evelo Biosciences pipeline, December 2019)
- 02 May 2019 Evelo Biosciences plans to introduce a new formulation of monoclonal microbials into ongoing clinical trials in second half of 2019